🎉 M&A multiples are live!
Check it out!

IDEAYA Biosciences Valuation Multiples

Discover revenue and EBITDA valuation multiples for IDEAYA Biosciences and similar public comparables like Vivoryon Therapeutics, Pharming, and Galapagos.

IDEAYA Biosciences Overview

About IDEAYA Biosciences

IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275/GSK959 (Werner Helicase), IDE161 (PARG), and IDE705/GSK101 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.


Founded

2015

HQ

United States of America
Employees

131

Website

ideayabio.com

Financials

LTM Revenue $9.6M

LTM EBITDA -$312M

EV

$841M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

IDEAYA Biosciences Financials

IDEAYA Biosciences has a last 12-month revenue of $9.6M and a last 12-month EBITDA of -$312M.

In the most recent fiscal year, IDEAYA Biosciences achieved revenue of $7.0M and an EBITDA of -$323M.

IDEAYA Biosciences expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See IDEAYA Biosciences valuation multiples based on analyst estimates

IDEAYA Biosciences P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $23.4M $7.0M XXX XXX XXX
Gross Profit n/a n/a XXX XXX XXX
Gross Margin NaN% NaN% XXX XXX XXX
EBITDA -$130M -$323M XXX XXX XXX
EBITDA Margin -558% -4616% XXX XXX XXX
Net Profit -$58.7M -$113M XXX XXX XXX
Net Margin -251% -1614% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

IDEAYA Biosciences Stock Performance

As of April 15, 2025, IDEAYA Biosciences's stock price is $17.

IDEAYA Biosciences has current market cap of $1.5B, and EV of $841M.

See IDEAYA Biosciences trading valuation data

IDEAYA Biosciences Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$841M $1.5B XXX XXX XXX XXX $-3.20

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

IDEAYA Biosciences Valuation Multiples

As of April 15, 2025, IDEAYA Biosciences has market cap of $1.5B and EV of $841M.

IDEAYA Biosciences's trades at 87.5x LTM EV/Revenue multiple, and -2.7x LTM EBITDA.

Analysts estimate IDEAYA Biosciences's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for IDEAYA Biosciences and 10K+ public comps

IDEAYA Biosciences Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $841M XXX XXX XXX
EV/Revenue 120.1x XXX XXX XXX
EV/EBITDA -2.6x XXX XXX XXX
P/E -5.5x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF -3.3x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get IDEAYA Biosciences Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

IDEAYA Biosciences Valuation Multiples

IDEAYA Biosciences's NTM/LTM revenue growth is 195%

IDEAYA Biosciences's revenue per employee for the last fiscal year averaged $0.1M, while opex per employee averaged $2.5M for the same period.

Over next 12 months, IDEAYA Biosciences's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate IDEAYA Biosciences's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for IDEAYA Biosciences and other 10K+ public comps

IDEAYA Biosciences Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth -70% XXX XXX XXX XXX
EBITDA Margin -4616% XXX XXX XXX XXX
EBITDA Growth 148% XXX XXX XXX XXX
Rule of 40 (SaaS-only) -4422% XXX XXX XXX XXX
Revenue per Employee $0.1M XXX XXX XXX XXX
Opex per Employee $2.5M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue 561% XXX XXX XXX XXX
R&D Expenses to Revenue 4210% XXX XXX XXX XXX
Opex to Revenue 4771% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

IDEAYA Biosciences Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

IDEAYA Biosciences M&A and Investment Activity

IDEAYA Biosciences acquired  XXX companies to date.

Last acquisition by IDEAYA Biosciences was  XXXXXXXX, XXXXX XXXXX XXXXXX . IDEAYA Biosciences acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by IDEAYA Biosciences

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About IDEAYA Biosciences

When was IDEAYA Biosciences founded? IDEAYA Biosciences was founded in 2015.
Where is IDEAYA Biosciences headquartered? IDEAYA Biosciences is headquartered in United States of America.
How many employees does IDEAYA Biosciences have? As of today, IDEAYA Biosciences has 131 employees.
Who is the CEO of IDEAYA Biosciences? IDEAYA Biosciences's CEO is Mr. Yujiro S. Hata.
Is IDEAYA Biosciences publicy listed? Yes, IDEAYA Biosciences is a public company listed on NAS.
What is the stock symbol of IDEAYA Biosciences? IDEAYA Biosciences trades under IDYA ticker.
When did IDEAYA Biosciences go public? IDEAYA Biosciences went public in 2019.
Who are competitors of IDEAYA Biosciences? Similar companies to IDEAYA Biosciences include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of IDEAYA Biosciences? IDEAYA Biosciences's current market cap is $1.5B
What is the current revenue of IDEAYA Biosciences? IDEAYA Biosciences's last 12-month revenue is $9.6M.
What is the current EBITDA of IDEAYA Biosciences? IDEAYA Biosciences's last 12-month EBITDA is -$312M.
What is the current EV/Revenue multiple of IDEAYA Biosciences? Current revenue multiple of IDEAYA Biosciences is 87.5x.
What is the current EV/EBITDA multiple of IDEAYA Biosciences? Current EBITDA multiple of IDEAYA Biosciences is -2.7x.
What is the current revenue growth of IDEAYA Biosciences? IDEAYA Biosciences revenue growth between 2023 and 2024 was -70%.
Is IDEAYA Biosciences profitable? Yes, IDEAYA Biosciences is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.